| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0190-9622(03)01134-4 |
| P698 | PubMed publication ID | 12894125 |
| P2093 | author name string | Kenneth B Gordon | |
| Stephanie L Mehlis | |||
| P2860 | cites work | Cytokines in psoriasis. | Q33632263 |
| Inflammatory skin diseases, T cells, and immune surveillance | Q33788959 | ||
| Current consensus and update on psoriasis therapy: a perspective from the U.S. | Q33817878 | ||
| Characterization of lymphocyte-dependent angiogenesis using a SCID mouse: human skin model of psoriasis | Q34124369 | ||
| Interaction of T cells with APCs: the serial encounter model | Q34198880 | ||
| Cutaneous lymphocyte antigen is a specialized form of PSGL-1 expressed on skin-homing T cells | Q34444540 | ||
| The majority of epidermal T cells in Psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiat | Q34505900 | ||
| T lymphocyte activation--an inside overview. | Q34567937 | ||
| Intercellular transfer of antigen-presenting cell determinants onto T cells: molecular mechanisms and biological significance. | Q34580022 | ||
| Biologic therapy for psoriasis: the new therapeutic frontier | Q34645976 | ||
| Psoriasiform eruption triggered by recombinant granulocyte-macrophage colony stimulating factor (rGM-CSF) and exacerbated by granulocyte colony stimulating factor (rG-CSF) in a patient with breast cancer | Q34656354 | ||
| Complexity in the major histocompatibility complex | Q36022934 | ||
| Relationships among antigen presentation, cytokines, immune deviation, and autoimmune disease | Q36365191 | ||
| Dermal injection of immunocytes induces psoriasis | Q37360845 | ||
| IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach | Q37378185 | ||
| Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis | Q40625955 | ||
| Characterization of Mononuclear Cell Infiltrates in Psoriatic Lesions | Q40693591 | ||
| Lymphocyte activation in health and disease | Q41420518 | ||
| Immune deviation towards Th2 inhibits Th-1-mediated autoimmune diabetes | Q41505445 | ||
| Immunocompetent cells in psoriasis. In situ immunophenotyping by monoclonal antibodies | Q41585682 | ||
| ELAM-1 is an adhesion molecule for skin-homing T cells | Q41694765 | ||
| Keratinocyte CDw60 expression is modulated by both a Th-1 type cytokine IFN-gamma and Th-2 cytokines IL-4 and IL-13: relevance to psoriasis | Q42499449 | ||
| Histological and immunocytochemical studies of human psoriatic lesions transplanted onto SCID mice | Q47803878 | ||
| Repeated subcutaneous injection of staphylococcal enterotoxin B-stimulated lymphocytes retains epidermal thickness of psoriatic skin-graft onto severe combined immunodeficient mice | Q47889608 | ||
| Administration of DAB389IL-2 to patients with recalcitrant psoriasis: a double-blind, phase II multicenter trial | Q47957463 | ||
| Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes | Q52018451 | ||
| Up-regulation of macrophage inflammatory protein-3 alpha/CCL20 and CC chemokine receptor 6 in psoriasis. | Q52026606 | ||
| Upregulation of RANTES in psoriatic keratinocytes: a possible pathogenic mechanism for psoriasis | Q52034964 | ||
| RANTES expression in psoriatic skin, and regulation of RANTES and IL-8 production in cultured epidermal keratinocytes by active vitamin D3 (tacalcitol) | Q52039933 | ||
| Pulling the trigger on psoriasis | Q59041460 | ||
| DAB486IL-2 (IL-2 Toxin) Selectively Inactivates High-Affinity IL-2 Receptor-Bearing Human Peripheral Blood Mononuclear Cells | Q67862531 | ||
| OKT3 first-dose reaction: association with T cell subsets and cytokine release | Q67984627 | ||
| Differential expression of GRO-alpha and IL-8 mRNA in psoriasis: a model for neutrophil migration and accumulation in vivo | Q71695986 | ||
| Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis | Q71803269 | ||
| T cells involved in psoriasis vulgaris belong to the Th1 subset | Q72238677 | ||
| Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions | Q72344499 | ||
| T-Lymphocyte Dependence of Psoriatic Pathology in Human Psoriatic Skin Grafted to SCID Mice | Q73666820 | ||
| Potential role of the chemokine receptors CXCR3, CCR4, and the integrin alphaEbeta7 in the pathogenesis of psoriasis vulgaris | Q73778362 | ||
| Different growth properties in response to epidermal growth factor and interleukin-6 of primary keratinocytes derived from normal and psoriatic lesional skin | Q74155554 | ||
| Zenapax (daclizumab) reduces the incidence of acute rejection episodes and improves patient survival following renal transplantation. No 14874 and No 14393 Zenapax Study Groups | Q74616021 | ||
| Expression of interleukin-12 is increased in psoriatic skin | Q77695850 | ||
| Combined analysis of polymorphisms of the tumor necrosis factor-alpha and interleukin-10 promoter regions and polymorphic xenobiotic metabolizing enzymes in psoriasis | Q78197650 | ||
| P433 | issue | 2 Suppl | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | immunology | Q101929 |
| immunotherapy | Q1427096 | ||
| P304 | page(s) | S44-50 | |
| P577 | publication date | 2003-08-01 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Journal of the American Academy of Dermatology | Q15757046 |
| P1476 | title | The immunology of psoriasis and biologic immunotherapy | |
| P478 | volume | 49 |
| Q36645644 | A treatment strategy for psoriasis: transitioning from systemic therapy to biologic agents |
| Q36993064 | Association Between Psoriasis and Subclinical Atherosclerosis: A Meta-Analysis |
| Q35095402 | Association of cytokine gene polymorphisms with psoriasis in cases from the nile delta of egypt |
| Q35834819 | Common clinical features and disease mechanisms of psoriasis and psoriatic arthritis |
| Q42524416 | Comparative study of histopathological and immunohistochemical findings in skin biopsies from patients with psoriasis before and after treatment with acitretin |
| Q42283126 | Current concepts in the pathogenesis of psoriasis |
| Q27654007 | Efalizumab binding to the LFA-1 L I domain blocks ICAM-1 binding via steric hindrance |
| Q36184302 | Efalizumab for the treatment of moderate to severe plaque psoriasis |
| Q45739352 | Evaluation of apoptosis regulatory proteins in response to PUVA therapy for psoriasis |
| Q46324197 | Expression of sirtuins 1, 6, tumor necrosis factor, and interferon-γ in psoriatic patients |
| Q35902661 | From laboratory to clinic: rationale for biologic therapy |
| Q43457583 | Hepatitis C and cutaneous alterations |
| Q36743142 | Immunobiologics in the treatment of psoriasis |
| Q51414778 | In vitro screening for putative psoriasis-specific antigens among wheat proteins and peptides |
| Q40460021 | Interferon-gamma-dependent in vitro model for the putative keratin 17 autoimmune loop in psoriasis: exploration of pharmaco- and gene-therapeutic effects. |
| Q37609371 | Management and costs of severe psoriasis: the role of new biologics |
| Q36502882 | New treatments for psoriasis: which biologic is best? |
| Q37664478 | Novel immunobiologics for psoriasis |
| Q53791065 | Pros and cons of biological therapy in psoriasis |
| Q53086507 | Psoriasis and cardiovascular risk factors: A case-control study on inpatients comparing psoriasis to dermatitis |
| Q56906257 | Safety and Efficacy of a Milk-Derived Extract in the Treatment of Plaque Psoriasis: An Open-Label Study |
| Q48678411 | Safety and efficacy of a fixed‐dose cyclosporin microemulsion (100 mg) for the treatment of psoriasis |
| Q38854675 | Serum levels of interleukin-8, tumor necrosis factor-α and γ-interferon in Egyptian psoriatic patients and correlation with disease severity. |
| Q36902900 | The role of dendritic cells in the immunopathogenesis of psoriasis |
| Q33571293 | Tolerability, pharmacokinetics and pharmacodynamics of CMAB001, an anti-CD11a antibody, in Chinese healthy volunteers and psoriatic patients |
| Q89942301 | Update on psoriasis: A review |
| Q46758055 | Very late antigen-1 in psoriasis: an immunohistochemical study |
| Q81746300 | [Clinical experience with etanercept in the treatment of psoriasis] |
| Q81057414 | [Treatment of severe refractory psoriasis with infliximab] |
Search more.